![ORI's Deal with Potti Doesn't Address The Role Duke Deans Played in Scandal](https://cdn.cancerletter.com/media/2015/11/22044015/41-42ORIs-Deal-with-Potti.jpg)
![ORI's Deal with Potti Doesn't Address The Role Duke Deans Played in Scandal](https://cdn.cancerletter.com/media/2015/11/22044015/41-42ORIs-Deal-with-Potti.jpg)
Cover Story
Free
After a five-year investigation, the HHS Office of Research Integrity announced that it has settled with former Duke University researcher Anil Potti.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” - A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital